Prices are updated after-hours

Cancer Nasdaq

Fennec Pharmaceuticals Inc.

FENC M | $10.5 -3.05% -3.14% 100K

(0.0% 1d) (-1.5% 1m) (35.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-29.88% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 284,598,668
http://www.fennecpharma.com
Sec Filling | Patents | 4 employees

(US) Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

cancer msa

add to watch list Paper trade email alert is off

Forma Therapeutics Holdings, Inc.

FMTX | $20.01 -0.15%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 957,529,666
https://formatherapeutics.com
Sec Filling | Patents | 105 employees

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

cancer prostate cancer t-cell treatment ceiling

add to watch list Paper trade email alert is off

Genocea Biosciences, Inc.

GNCA | $0.051

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-15.0% 3d) (0.0% 7d) (-35.74% volume)
Earnings Calendar: 2022-08-04
Market Cap:
http://www.genocea.com
Sec Filling | Patents | 59 employees

(US) Genocea Biosciences, Inc. engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

vaccine cancer immunotherapy t-cell genetic treatment ceiling

add to watch list Paper trade email alert is off

Harpoon Therapeutics, Inc.

HARP | $23.01 0.07% 6.6M

Health Technology

(0.0% 1d) (0.0% 1m) (3796.6% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees

(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

cancer immunotherapy glass t-cell treatment ceiling construction

add to watch list Paper trade email alert is off

Bellicum Pharmaceuticals, Inc.

BLCM | $0.0748 381.28% 6.1K

Health Technology

(0.0% 1d) (0.0% 1m) (-77.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3229.12% volume)
Earnings Calendar: 2022-11-03
Market Cap: $ 726,826
http://www.bellicum.com
Sec Filling | Patents | 107 employees

(US) Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX.

cancer immunotherapy

add to watch list Paper trade email alert is off

BriaCell Therapeutics Corp.

BCTX | $2.19 -5.6% -5.94% 140K

Professional, Scientific, and T...

(0.0% 1d) (-3.2% 1m) (-61.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 34,999,980
https://www.briacell.com
Sec Filling | Patents | 2022 employees

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

cancer

add to watch list Paper trade email alert is off

Calithera Biosciences, Inc.

CALA | $0.04 150.0% 5.3K

Health Technology

(0.0% 1d) (150.0% 1m) (25.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-28.37% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 194,900
http://www.calithera.com
Sec Filling | Patents | 93 employees

(US) Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

cancer t-cell molecule drugs metabolic ceiling

add to watch list Paper trade email alert is off

Celyad SA

CYAD | $0.47 -12.49% 49K

Health Technology

(0.0% 1d) (0.0% 1m) (-33.5% 1y) (0.0% 2d) (-11.1% 3d) (0.0% 7d) (421.67% volume)
Earnings Calendar:
Market Cap: $ 10,619,159
http://www.celyad.com
Sec Filling | Patents | 107 employees

(BE) Celyad Oncology SA engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

cancer cardiology car-t t-cell treatment ceiling

add to watch list Paper trade email alert is off

Checkmate Pharmaceuticals, Inc.

CMPI | $10.5 0.0%

Health Technology

(0.0% 1d) (0.2% 1m) (0.0% 1y) (0.2% 2d) (0.1% 3d) (0.0% 7d) (-49.8% volume)
Earnings Calendar: 2022-08-11
Market Cap:
http://www.checkmatepharma.com
Sec Filling | Patents | 22 employees

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. It specializes in the field of CpG oligonucleotides. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA.

cancer

add to watch list Paper trade email alert is off

ChemoCentryx, Inc.

CCXI | News | $51.99 -0.04%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (160.14% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 3,709,791,785
http://www.chemocentryx.com
Sec Filling | Patents | 82 employees

(US) ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

cancer autoimmunity

add to watch list Paper trade email alert is off

Clovis Oncology, Inc.

CLVS | $0.0812 -3.94%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (26.22% volume)
Earnings Calendar: 2023-02-22
Market Cap: $ 11,770,367
http://www.clovisoncology.com
Sec Filling | Patents | 484 employees

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer; and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

acquisitions cancer prostate cancer liver treatment cancer treatments

Drugs

Rubraca (rucaparib)

add to watch list Paper trade email alert is off

Aptose Biosciences, Inc.

APTO | $1.3 -4.41% -4.62% 62K

Health Technology

(0.0% 1d) (-6.6% 1m) (-80.5% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (425.63% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 20,433,011
http://aptose.com
Sec Filling | Patents | 33 employees

(CA) Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

cancer

add to watch list Paper trade email alert is off

Aravive, Inc.

ARAV | $0.0401 4.74% 4M

Health Technology

(0.0% 1d) (0.0% 1m) (-97.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-85.6% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 2,949,862
http://www.aravive.com
Sec Filling | Patents | 17 employees

(US) Aravive, Inc. is a clinical-stage biotechnology company, which engages in developing new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments, and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX.

cancer t-cell ovarian cancer treatment ceiling

add to watch list Paper trade email alert is off

Athenex, Inc.

ATNX | $0.2031 -7.78% 1.9M

Health Technology

(0.0% 1d) (0.0% 1m) (-83.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (199.02% volume)
Earnings Calendar: 2022-10-27
Market Cap: $ 1,759,498
http://www.athenex.com
Sec Filling | Patents | 574 employees

(US) Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients (APIs) for clinical and commercial efforts. The Commercial Platform segment involves in the sales and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

cancer tirbanibulin treatment

add to watch list Paper trade email alert is off

Humanigen, Inc.

HGEN | $0.0361 -61.5% 120M

Health Technology

(0.0% 1d) (0.0% 1m) (-77.3% 1y) (0.0% 2d) (0.0% 3d) (-81.1% 7d) (23283.32% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 4,298,793
http://www.humanigen.com
Sec Filling | Patents | 2 employees

(US) Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

cancer gene therapies t-cell treatment ceiling

add to watch list Paper trade email alert is off

ImmunoGen, Inc.

IMGN | News | $31.23 0.03% 49M

Health Technology

(0.0% 1d) (0.0% 1m) (673.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 8,315,433,277
http://www.immunogen.com
Sec Filling | Patents | 75 employees

(US) ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.

cancer antibody

add to watch list Paper trade email alert is off

IMV Inc.

IMV | $0.8225 -2.74% 45K

Health Technology

(0.0% 1d) (0.0% 1m) (-9.6% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.

vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling

add to watch list Paper trade email alert is off

Infinity Pharmaceuticals, Inc.

INFI | $0.016 12.5% 1.1M

Health Technology

(0.0% 1d) (0.0% 1m) (-90.4% 1y) (-4.8% 2d) (28.0% 3d) (0.0% 7d) (264.12% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 1,452,177
http://www.infi.com
Sec Filling | Patents | 25 employees

(US) Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

cancer msa

add to watch list Paper trade email alert is off

Jounce Therapeutics, Inc.

JNCE | $1.88 -2.59% -1.85% 0

Health Technology

(0.0% 1d) (0.0% 1m) (0.5% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-05-04
Market Cap: $ 98,954,680
http://www.jouncetx.com
Sec Filling | Patents | 130 employees

(US) Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

cancer immunotherapy t-cell ceiling

add to watch list Paper trade email alert is off

Enochian Biosciences, Inc.

ENOB 4 | $0.7 0.0% 88K

Health Technology

(0.0% 1d) (0.0% 1m) (-37.5% 1y) (0.0% 2d) (8.4% 3d) (0.0% 7d) (-22.33% volume)
Earnings Calendar:
Market Cap: $ 40,798,514
http://www.enochianbio.com
Sec Filling | Patents | 10 employees

(US) Enochian Biosciences, Inc. engages in the development of genetically modified cellular and immune-therapy technologies for treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev on January 18, 2011 and is headquartered in Los Angeles, CA.

cancer immunotherapy infectious disease genetic hiv treatment

add to watch list Paper trade email alert is off